Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, 2/9/2022
Management will host a conference call on Wednesday February 9, 2022, at 4:30 pm ET to review financial (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tues. May 10, 2022
Management will host a conference call on Tuesday May 10, 2022, at 4:30 pm ET to review financial results (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Reports Fiscal Second Quarter 2017 Financial Results
years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com Social Media: Bill Douglass Gotham
- Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- BIO CEO & Investor Conference 2017 Panel "Designing Clinical Trials in 21st Century Cures Paradigm"
Eastern Time Location: The Waldorf Astoria Hotel in New York, NY https://www.bio.org/events/bio-ceo-investor-conference
- Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
